1. Herman, B. H., Vocci, F., and Bridge, P. (1995) The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacol-ogy 13, 269-293.

2. Trujillo, K. A. (1995) Effects of noncompetitive N-methyl-d-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 13, 301-307.

3. Bisaga, A. and Popik, P. (2000) In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-d-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59,1-15.

4. Bisaga, A., et al. (2000) Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. Expert Opin. Investig. Drugs 9, 2233-2248.

5. Herman, B. H., et al. (2001) Glutamate and Addiction (Herman, B. H., ed.), Human, Totowa, NJ.

6. Bergman, J., et al. (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Ber.) 153, 67-84.

7. McCance-Katz, E. F., Kosten, T. A., and Kosten, T. R. (2001) Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology (Ber.) 155, 327-329.

8. McCance-Katz, E. F. (1997) Medication development for the treatment of cocaine dependence: issues in clinical efficacy trials. NIDA Res. Monogr. 175, 36-72.

9. Fischman, M. W. and Foltin, R. W. (1998) Cocaine self-administration research: implication for rational pharmacotherapy, in Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications (Higgins, S. T. and Katz, J. L., eds.), Academic, San Diego, CA, pp. 181-207.

10. Nunes, E. V. (1997) Methodologic recommendations for cocaine abuse clinical trials: a clinician-researcher's perspective. NIDA Res Monogr 175, 73-95.

11. Bigelow, G. E. and Walsh, S. L. (1998) Evaluation of potential pharmacotherapies: response to cocaine challenge in the human laboratory, in Cocaine Abuse: Behavior, Pharmacology, and Clinical Applications (Higgins, S. T. and Katz, J. L., eds.) Academic, San Diego, CA, pp. 209-238.

12. Comer, S. D., Collins, E. D., and Fischman, M. W. (2001) Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology (Ber.) 154, 28-37.

13. Ernst, M. and London, E. D. (1997) Brain imaging studies of drug abuse: therapeutic implications. Semin. Neurosci. 9, 120-130.

14. Kosten, T. A. (1992) Pharmacotherapies, in Clinician's Guide to Cocaine Addiction: Theory, Research, and Treatment (Kosten, T.A. and Kleber, H.D., eds.), Guilford, New York.

15. Kolb, L. and Himmelsbach, C. K. (1938) A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am. J. Psychiatry 94, 759-799.

16. Fraser, H. F. and Isbell, H. (I960) Human pharmacology and addction liabilities of pentazocine and levophenacylmorphan. Bull. Narcot. 12, 15-23.

17. Jasinski, D. R., Martin, W. R., and Haertzen, C. A. (1967) The human pharmacology and abuse potential of N-allylnoroxy-morphone (naloxone). J. Pharmacol. Exp. Ther. 157, 420-426.

18. Rosen, M. I., McMahon, T. J., Hameedi, F. A., Pearsall, H. R., Woods, S. W., Kreek, M. J., and Kosten, T. R. (1996) Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. J. Pharmacol. Exp. Ther. 276, 1128-1135.

19. Isbell, H. and Fraser, H. F. (1953) Actions and addiction liabilities of dromoran derivatives in man. J. Pharmacol. Exp. Ther. 106, 524-530.

20. Rosen, M. I., McMahon, T. J., Woods, S. W., Pearsall, H. R., and Kosten, T. R. (1996) A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. Eur. J. Pharmacol. 307, 251-257.

21. Steinberg, G. K., Bell, T. E., and Yenari, M. A. (1996) Dose escalation safety and tolerance study of the N-methyl-d-aspartate antagonist dextromethorphan in neurosurgery patients. J. Neurosurg. 84, 860-866.

22. Cornish, J. W., Herman, B. H., Ehrman, R. N., Robbins, S. J., Childress, A. R., Bead, V., Esmonde, C. A., Martz, K., Poole, S., Caruso, F. S., Vocci, F., and O'Brien, P. A randomized, double-bline, placebo- controlled safety study of high-dose dex-tromethorphan in methadone- maintained male patients. Drug Alcohol Depend., in press.

23. Jasinski, D. R. (2000) Abuse potential of morphine/dextromethorphan combinations. J. Pain Symptom Manage. 19, (Suppl) 26-S30.

24. Bisaga, A., Comer, S. D., Ward, A. S., Popik, P., Kleber, H. D., and Fischman, M. W. (2001) The NMDA antagonist meman-tine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl.) 157(1), 1-10.

25. Rosen, M. I., Persall, H. R., and Kosten, T. R. (1998) The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Depend. 52, 173-176.

26. Mello, N. K., Mendelson, J. H., Kuehnle, J. C., and Sellers, M. S. (1981) Operant analysis of human heroin self- administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. 216, 45-54.

27. Collins, E. D., Ward, A. S., McDowell, D. M., Foltin, R. W., and Fischman, M. W. (1998) The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav. pharmacol. 9(7): 587-598.

28. Hyytia, P., Backstrom, P., and Liljequist, S. (1999) Site-specific NMDA receptor antagonists produce differential effects on cocaine self- administration in rats. Eur. J. Pharmacol. 378, 9-16.

29. Pulvirenti, L., Balducci, C., and Koob, G. F. (1997) Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321, 279-283.

30. Kantak, K. M., Edwards, M. A., and O'Connor, T. P. (1998) Modulation of the discriminative stimulus and rate-altering effects of cocaine by competitive and noncompetitive N-methyl-d-aspartate antagonists. Pharmacol. Biochem. Behav. 59, 159-169.

31. Herman, B. H. and O'Brien, C. P. (1997) Clinical medication development for opiate addiction: focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin. Neurosci. 9, 158-172.

32. Koyuncuoglu, H. and Saydam, B. (1990) The treatment of heroin addicts with dextromethorphan. A double- blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. 28, 147-152.

33. Koyuncuoglu, H. (1991) The treatment with dextromethorphan of heroin addicts, in Drug Addiction and AIDS (Loimer, N., Schmid, R., and Springer, A., eds.), Springer-Verlog, Vienna, pp. 320-329.

34. Koyuncuoglu, H. (1995) The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int. J. Clin. Pharmacol. Ther. 33,13-19.

35. O'Connor, P. G., Carroll, K. M., Shi, J. M., Schottenfeld, R. S., Kosten, T. R., and Rounsaville, B. J. (1997) Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann. Intern. Med. 127, 526-530.

36. Washton, A. M. and Resnick, R. B. (1980) Clonidine for opiate detoxification: outpatient clinical trials. Am. J. Psychiatry 137,1121-1122.

37. Bisaga, A., Gianelli, P., and Popik, P. (1997) Opiate withdrawal with dextromethorphan. Am. J. Psychiatry 154, 584.

38. Bisaga, A., Comer, S. D., Akerele, E. O., Kleber, H. D., and Fischman, M. W. (1999) The clinical use of memantine in opioid detoxification. NIDA Res. Monogr. 180, 227.

39. Popik, P., Layer, R. T., and Skolnick, P. (1995) 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47, 235-253.

40. De Rienzo, P., Beal, D., and Staff, P. M. (1997) The Ibogaine Story: Report on the Staten Island Project. Autonomedia, Brooklyn, NY.

41. Alper, K. R., Lostof, H. S., Frenken, G. M., Luciano, D. J., and Bastiaans, J. (1999) Treatment of acute opioid withdrawal with ibogaine. Am. J. Addict. 8, 234-242.

42. Kovera, C. A., Kovera, M. B., Singleton, E. G., Ervin, F. R., Williams, I. C., and Mash, D. C. (1998) Decreased drug craving during inpatient detoxification with ibogaine. NIDA Res. Monogr. 179, 294.

43. Mash, D. C., et al. (2000) Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann. NY Acad. Sci. 914, 394-401.

44. Sheppard, S. G. (1994) A preliminary investigation of ibogaine: case reports and recommendations for further study. J. Subst. Abuse Treat. 11, 379-385.

45. Kornhuber, J., Weller, M., Schoppmeyer, K., and Riederer, P. (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural Transm. 43(Suppl.), 91-104.

46. Giannini, A. J., Folts, D. J., Feather, J. N., and Sullivan, B. S. (1989) Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res. 29,11-16.

47. Tennant, F. S., Jr. and Sagherian, A. A. (1987) Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Intern. Med. 147, 109-112.

48. Gawin, F. H., Morgan, C., Kosten, T. R., and Kleber, H. D.(1989) Double-blind evaluation of the effect of acute amantadine on cocaine craving. Psychopharmacology (Berl.) 97, 402-403.

49. Morgan, C., Kosten, T., Gawin, F., and Kleber, H. (1988) A pilot trial of amantadine for ambulatory withdrawal for cocaine dependence. NIDA Res. Monogr. 81, 81-85.

50. Thompson, D. F. (1992) Amantadine in the treatment of cocaine withdrawal. Ann. Pharmacother. 26, 933-934.

51. Kampman, K. M., Volpicelli, J. R., Alterman, A. I., Cornish, J., and O'Brien, C. P. (2000) Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am. J. Psychiatry 157, 2052-2054.

52. Bespalov, A., Zvartau, E. E., Krupitsky, E. M., Mosolov, D. V., and Burakov, A. M. (2001) A pilot study of memantine for the treatment of heroin dependence. Drug Alcohol Depend 63,14 (abstract).

53. Alterman, A. I., Droba, M., Antelo, R. E., Cornish, J. W., Sweeney, K. K., Parikh, G. A., and O'Brien, C. P. (1992) Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 31, 19-29.

54. Ziedonis, D. M. and Kosten, T. R. (1991) Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J. Psychoactive Drugs 23, 417-425.

55. Shoptaw, S., Kintaudi, K., Charuvastra, V. C., Rawson, R. A., and Ling, W. (1998) Amantadine hydrochloride is effective treatment for cocaine dependence. NIDA Res. Monogr. 179, 55.

56. Kolar, A. F., Brown, B. S., Weddington, W. W., Haertzen, C. C., Michaelson, B. S., and Jaffe, J. H. (1992) Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 27, 849-868.

57. Kosten, T. R., Morgan, C. M., Falcione, J., and Schottenfeld, R. S. (1992) Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry 49, 894-898.

58. Weddington, W. W., Brown, B. S., Haertzen, C. A., Hess, J. M., Kolar, A. F., and Mahaffey, J. R. (1989) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. NIDA Res. Monogr. 95, 483-484.

59. Handelsman, L., Limpitlaw, L., Williams, D., Schmeidler, J., Paris, P., and Stimmel, B. (1995) Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend. 39, 173-180.

60. Kampman, K., Volpicelli, J. R., Alterman, A., Cornish, J., Weinreib, R., Epperson, L., Sparkman, T., and O'Brien, C. P. (1996) Amantadine in the early treatment of cocaine dependence: a double- blind, placebo-controlled trial. Drug Alcohol Depend. 41, 25-33.

Natural Detox

Natural Detox

Are you looking for a full total body detox? If so, then you might want to try a 10 day detox or some refer to it as the 2-week detox. A 10-day detox is a full body detox that usually means taking several different steps to reach your total body transformation. It might involve a change in diet, exercise and more.

Get My Free Ebook

Post a comment